升荣口服液联合肝动脉介入化疗栓塞治疗原发性肝癌疗效及机制研究  

The effect of Sheng Rong oral liquid combined with transcatheter arterial chemoembolization(TACE) in the treatment of primary hepatocellular carcinoma

作　　者：喻小静[1] 蔡惠[2] 李强[1] 陈萌[1] 贺启华[1] 范志刚[1] YU Xiao-ring;CAI Hui;LI Qiang;FAN Zhi-gang(Department of Oncology;Hanzhong 3201 Hospital Affiliated to Medical College of Xi＇an Jiao Tong University（Hanzhong Shanxi,723000）China)

机构地区：[1]西安交通大学医学院附属汉中3201医院肿瘤科,陕西汉中723000 [2]西安交通大学第一附属医院血管外科

出　　处：《中西医结合肝病杂志》2018年第5期275-277,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：陕西省科技厅科技研究发展计划项目(2005K16-G4)

摘　　要：目的:观察升荣口服液联合肝动脉介入化疗栓塞(TACE)治疗原发性肝癌疗效与患者免疫功能等的变化。方法:按照课题设计共纳入87例患者,按照随机数字表法分为TACE联合组(升荣口服液+TACE)和对照组(TACE),观测指标包括:肿瘤评定、生存质量、免疫功能、血常规及肝肾功能等安全性指标。结果:TACE联合组治疗有效率77. 27%优于对照组55. 81%(P <0. 05),生活质量评分、外周血三系细胞及免疫细胞指数等方面均较对照组改善,差异具有显著性(P <0. 05),毒副作用比较无显著性差异(P> 0. 05)。结论:升荣口服液联合TACE治疗原发性肝癌能改善患者生存质量、提高免疫、抑制肿瘤,毒副作用可控,具有临床应用价值。Objective： To observe the effect and immune function of Sheng Rong oral liquid combined with transcatheter arterial chemoembolization （TACE） in the treatment of primary hepatocellular carcinoma. Methods：According to the design of the project, 87 patients were divided into Tace combined group （ShengRong Oral liquid ＋ tace） and control group （TACE） according to the Random digital table method, and the observation indexes included： tumor evaluation, quality of life,immune function, blood picture and side effects. Results： The effective rate of 77.27% in Tace Group was better than that in control group,55.81% （P 〈 0. 05）, quality of life score, peripheral blood tri - cell and immune cell index were all better than those in control group, the difference was significant （P 〈 0.05）, there was no significant difference of toxicity （P 〉 0.05 ）. Conclusion： Shengrong oral liquid combined with TACE in the treatment of primary liver cancer can improve the quality life of patients, improve immunity,inhibit tumor, toxicity and controllable, has clinical application value.

关 键 词：升荣口服液 肿瘤 放疗 化疗 生存质量 

分 类 号：R735.7[医药卫生—肿瘤]